The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Multiple myeloma (MM) is characterized by remarkable cytogenetic/molecular heterogeneity among patients and intraclonal diversity even in a single patient. We previously demonstrated that PDPK1, the master kinase of series of AGC kinases, is universally active in MM, and plays pivotal roles in cell proliferation and cell survival of myeloma cells regardless of the profiles of cytogenetic and genetic abnormalities. This study investigated the therapeutic efficacy and mechanism of action of dual blockade of two major PDPK1 substrates, RSK2 and AKT, in MM. The combinatory treatment of BI-D1870, an inhibitor for N-terminal kinase domain (NTKD) of RSK2, and ipatasertib, an inhibitor for AKT, showed the additive to synergistic anti-tumor effect on human MM-derived cell lines (HMCLs) with active RSK2-NTKD and AKT, by enhancing apoptotic induction with BIM and BID activation. Moreover, the dual blockade of RSK2 and AKT exerted robust molecular effects on critical gene sets associated with myeloma pathophysiologies, such as those with MYC, mTOR, STK33, ribosomal biogenesis, or cell-extrinsic stimuli of soluble factors, in HMCLs. These results provide the biological and molecular rationales for the dual-targeting strategy for RSK2 and AKT, which may overcome the therapeutic difficulty due to cytogenetic/molecular heterogeneity in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The PI3K/AKT/mTOR signaling pathway plays a crucial role in MM pathogenesis by regulating various cellular processes such as proliferation, migration, apoptosis, and autophagy.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This pathway is frequently activated in MM due to oncogenic events and extrinsic stimulation [65].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 1×
“org, accessed on 1 December 2021) [32,67].”
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 1×
“DRI = 1 indicates no dose reduction, whereas DRI > 1 and <1 indicate favorable and unfavorable dose-reduction, respectively [66].”
BackgroundHeterogeneity of genomic evolution and mutational profiles in multiple myeloma
Bolli, N., Avet-Loiseau, H., Wedge, D. C., Van Loo, P., Alexandrov, L. B., Martincorena, I., Dawson, K. J., Iorio, F., Nik-Zainal, S., Bignell, G. R., et al. (2014) · Nature Communications · doi:10.1038/ncomms3997 · Cited by 875
Multiple myeloma epidemiology and survival: A unique malignancy
Kazandjian, D. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.11.004 · Cited by 765 · cited 1×
“Multiple myeloma (MM) is a clonal plasma cell neoplasm, and is the second most common hematologic malignancy [1].”
BackgroundIRF4 addiction in multiple myeloma
Shaffer, A. L., Emre, N. C. T., Lamy, L., Ngo, V. N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., et al. (2008) · Nature · doi:10.1038/nature07064 · Cited by 730
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F. E., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2018) · Blood · doi:10.1182/blood-2018-03-840132 · Cited by 475
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0196-8 · Cited by 446
Görgün, G. T., Whitehill, G., Anderson, J. L., Hideshima, T., Maguire, C., Laubach, J., Raje, N., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2013) · Blood · doi:10.1182/blood-2012-08-448548 · Cited by 393
Regulation and function of the RSK family of protein kinases
Romeo, Y., Zhang, X., & Roux, P. P. (2012) · Biochemical Journal · doi:10.1042/bj20110289 · Cited by 377 · cited 1×
“of RAS/RAF/ERK pathway [39,40], the therapeutic effect of single targeting of RAS or RAF might be hampered by the PDPK1-mediated constitutive active status of RSK2, which is independent of RAS/RAF/ERK activity in myeloma cells, while the blockade of AKT alone has only cytostatic effects but no major cell killing effec…”
BackgroundCragg, M. S., Kuroda, J., Puthalakath, H., Huang, D. C. S., & Strasser, A. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040316 · Cited by 343
Self-citation
Cited by
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Hu, S., Xu, J., Cui, W., Jin, H.-R., Wang, X., & Maimaitiyiming, Y. (2025) · Biomolecules · doi:10.3390/biom15050702 · Cited by 11
“INPP4B enhances the efficacy of bortezomib by suppressing phosphorylation of Akt at Ser473, thereby attenuating PI3K/Akt/mTOR pathway activity, whereas loss of INPP4B leads to Akt hyperactivation and drug resistance [120–122].”
Doi, T., Takahashi, S., Aoki, D., Yonemori, K., Hara, H., Hasegawa, K., Takehara, K., Harano, K., Yunokawa, M., Nomura, H., et al. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04631-7 · Cited by 9
Karathanasis, N., & Spyrou, G. M. (2025) · Cancers · doi:10.3390/cancers17020332 · Cited by 10
“For instance, the PI3K-Akt pathway has been widely recognized as a key player in MM, influencing proliferation, migration, apoptosis, and autophagy [43].”
Katsuragawa‐Taminishi, Y., Mizutani, S., Kawaji‐Kanayama, Y., Onishi, A., Okamoto, H., Isa, R., Mizuhara, K., Muramatsu, A., Fujino, T., Tsukamoto, T., et al. (2023) · Cancer Science · doi:10.1111/cas.15995 · Cited by 6
“10,11 14 Importantly, the PDPK1/RSK2 signaling axis is universally active in MCL and MM, and the blockade of this pathway has antitumor effects, regardless of cytogenetic/molecular manifestations in MM. 10–14 These evoke the idea of further investigating the values of PDPK1 and its effector…”
BackgroundSelf-citation
Metadata
- Authors
- Isa, R., Horinaka, M., Tsukamoto, T., Mizuhara, K., Fujibayashi, Y., Taminishi-Katsuragawa, Y., Okamoto, H., Yasuda, S., Kawaji-Kanayama, Y., Matsumura-Kimoto, Y., Mizutani, S., Shimura, Y., Taniwaki, M., Sakai, T., & Kuroda, J.
- Affiliations
- Kyoto Prefectural University of Medicine (JP)
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
- Corresponding author
- Kuroda, Junya
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-03-08
- Volume
- 23
- Issue
- 6
- Pages
- 2919
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8949999
- OpenAlex
- W4220992956
- Semantic Scholar
- 1f38141255b372f5b40f14a121ef47766edbf526
- Cited by
- 11
- References
- 67
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 1
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (19K08872)
- The Japanese Society Hematology Research Grant (N.A.)
- The Japan Leukemia Research Fund Award (N.A.)
- Japan Agency for Medical Research and Development (JP19ck0106516h0001)
- Japanese Society for Myeloma Research Award (N.A.)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, RSK2, Akt, PDPK1, dual-targeted therapy, BI-D1870, ipatasertib, AGC kinases, apoptosis, building information modeling, Bid, c-Myc, mTOR, STK33, ribosome biogenesis, cytogenetic heterogeneity, combination therapy
- MeSH terms
- Humans, Multiple Myeloma, Protein Serine-Threonine Kinases, Ribosomal Protein S6 Kinases, 90-kDa, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-akt, 3-Phosphoinositide-Dependent Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma. https://app.cochat.ai/papers/10.3390/ijms23062919
- The paper
- Isa, R., Horinaka, M., Tsukamoto, T., Mizuhara, K., Fujibayashi, Y., Taminishi-Katsuragawa, Y., Okamoto, H., Yasuda, S., Kawaji-Kanayama, Y., Matsumura-Kimoto, Y., Mizutani, S., Shimura, Y., Taniwaki, M., Sakai, T., & Kuroda, J. (2022). The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms23062919
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.